IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
May 03 2021 - 8:00AM
Business Wire
IQVIA (NYSE: IQV) announced today that it will collaborate with
Corium, Inc – a commercial-stage biopharmaceutical company leading
the development and commercialization of novel central nervous
system (CNS) therapies – to support the launch of AZSTARYS™, which
was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the
first and only product containing a dexmethylphenidate (d-MPH) oral
prodrug for the treatment of attention deficit hyperactivity
disorder (ADHD) symptoms in patients aged six years and older.
“This is an exciting milestone for Corium as we prepare to bring
AZSTARYS to market and provide patients with ADHD and their
clinicians a new option for rapid and extended symptom control,”
said Perry J. Sternberg, President and CEO of Corium. “To
successfully do this, we need a partner with the expertise,
resources, and technology to help us efficiently engage with
clinicians and connect the right patients to this treatment. We are
thrilled to be partnering with IQVIA to support and execute our
commercialization strategy for AZSTARYS.”
Under the agreement, IQVIA will deploy a tailored combination of
technology, analytics, and field services to enable coordinated,
effective engagements with healthcare professionals who treat ADHD.
IQVIA’s team of sales reps and medical liaisons will complement
Corium’s deep internal ADHD and commercialization expertise and
customer-facing leadership. Corium will also be supported by
IQVIA’s Orchestrated Customer Engagement (OCE) SaaS-based platform,
which connects sales, marketing, and medical with AI-enabled
recommendations through an intuitive and efficient user
experience.
“This is an excellent example of how IQVIA’s depth of expertise
and breadth of offerings can support companies that are launching
for the first time and need to maximize every engagement,” said
Susan Kitlas, a vice president of sales dedicated to pre-commercial
clients. “Leveraging IQVIA Connected Intelligence, Corium will be
able to tap into the data, technology, analytics, and other
resources they need to commercialize with speed, agility, and
scale. We look forward to supporting Corium and bringing this
valuable medicine to market for patients and families managing
ADHD.”
About IQVIA IQVIA (NYSE:IQV) is a leading global provider
of advanced analytics, technology solutions, and clinical research
services to the life sciences industry. IQVIA creates intelligent
connections across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210503005234/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Nick Childs, IQVIA Investor Relations (Nchilds@us.imshealth.com)
+1.973.316.3828
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024